Literature DB >> 19129251

Aicardi-Goutieres syndrome.

S Orcesi1, R La Piana, E Fazzi.   

Abstract

INTRODUCTION: Aicardi-Goutières syndrome (AGS) is an autosomal recessive encephalopathy characterized by acquired microcephaly, cerebral calcifications, leukodystrophy, cerebral atrophy and cerebrospinal fluid findings of chronic lymphocytosis and raised interferon-alpha (INF-alpha). The main extraneurological symptoms are chilblain-like skin lesions, usually on the fingers, toes and ears. SOURCES OF DATA: This review is based on a search of the published literature on AGS from 1984 onwards (particularly the most recent papers) and on knowledge and experience gained through the authors' work with the International Aicardi-Goutières Syndrome Association (IAGSA). AREAS OF AGREEMENT: It is accepted that AGS can be mistaken for a congenital infection and that the diagnostic significance of its cardinal signs (raised INF-alpha levels, basal ganglia calcifications) is different in different stages of the disease. Currently, we know of four genes that, if mutated, can give rise to AGS, but at least one other gene is believed to exist. These genes are involved in the DNA damage response, a defect of which could provoke an inappropriate innate immune response, triggering increased secretion of INF-alpha, ultimately responsible for the main features of the disease. AREAS OF CONTROVERSY: The natural history of AGS has not yet been definitively described given the lack of extensive, long-term neuroradiological follow-up studies. Furthermore, it is not yet clearly understood how the innate immune system is activated, what triggers the onset of the disease or why it tends to 'burn out' after several months. Immunosuppressive therapy in the active stage of the disease does not seem to produce any real change in the clinical course, but more data are needed. GROWING POINTS AND AREAS TIMELY FOR DEVELOPING RESEARCH: Current studies aim to clarify the molecular mechanisms underlying the pathogenesis of AGS and to establish the exact pathway by which retained nucleic acids activate the immune system. This knowledge could allow the development of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129251     DOI: 10.1093/bmb/ldn049

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  21 in total

1.  Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31.

Authors:  Geneviève Bernard; Isabelle Thiffault; Martine Tetreault; Maria Lisa Putorti; Isabelle Bouchard; Michel Sylvain; Serge Melançon; Rachel Laframboise; Pierre Langevin; Jean-Pierre Bouchard; Michel Vanasse; Adeline Vanderver; Guillaume Sébire; Bernard Brais
Journal:  Neurogenetics       Date:  2010-07-17       Impact factor: 2.660

2.  Aicardi-Goutières syndrome is caused by IFIH1 mutations.

Authors:  Hirotsugu Oda; Kenji Nakagawa; Junya Abe; Tomonari Awaya; Masahide Funabiki; Atsushi Hijikata; Ryuta Nishikomori; Makoto Funatsuka; Yusei Ohshima; Yuji Sugawara; Takahiro Yasumi; Hiroki Kato; Tsuyoshi Shirai; Osamu Ohara; Takashi Fujita; Toshio Heike
Journal:  Am J Hum Genet       Date:  2014-07-03       Impact factor: 11.025

Review 3.  Acrocyanosis: the Flying Dutchman.

Authors:  Andrew K Kurklinsky; Virginia M Miller; Thom W Rooke
Journal:  Vasc Med       Date:  2011-03-22       Impact factor: 3.239

4.  A large homozygous deletion in the SAMHD1 gene causes atypical Aicardi-Goutiéres syndrome associated with mtDNA deletions.

Authors:  Esther Leshinsky-Silver; Gustavo Malinger; Liat Ben-Sira; Dvora Kidron; Sarit Cohen; Shani Inbar; Tali Bezaleli; Arie Levine; Chana Vinkler; Dorit Lev; Tally Lerman-Sagie
Journal:  Eur J Hum Genet       Date:  2010-11-24       Impact factor: 4.246

5.  Leukoencephalopathy, cerebral calcifications and cysts: a family study.

Authors:  Kinga Karlinger; Ádám Domonkos Tárnoki; Dávid László Tárnoki; Anne Polvi; Anna-Elina Lehesjoki; Andrea Kelemen; László Szegedi; Eszter Turányi; Anita Kamondi; Anna Szűcs
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

Review 6.  Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.

Authors:  Hanna Kim; Gina A Montealegre Sanchez; Raphaela Goldbach-Mansky
Journal:  J Mol Med (Berl)       Date:  2016-09-27       Impact factor: 4.599

7.  Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation.

Authors:  Sebastiano La Maestra; Guido Frosina; Rosanna T Micale; Chiara D'Oria; Silvano Garibaldi; Antonio Daga; Alessandra Pulliero; Alberto Izzotti
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

8.  Early-Onset Aicardi-Goutières Syndrome: Magnetic Resonance Imaging (MRI) Pattern Recognition.

Authors:  Adeline Vanderver; Morgan Prust; Nadja Kadom; Scott Demarest; Yanick J Crow; Guy Helman; Simona Orcesi; Roberta La Piana; Carla Uggetti; Jichuan Wang; Heather Gordisch-Dressman; Marjo S van der Knaap; John H Livingston
Journal:  J Child Neurol       Date:  2014-12-22       Impact factor: 1.987

9.  Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome.

Authors:  Roberta La Piana; Carla Uggetti; Federico Roncarolo; Adeline Vanderver; Ivana Olivieri; Davide Tonduti; Guy Helman; Umberto Balottin; Elisa Fazzi; Yanick J Crow; John Livingston; Simona Orcesi
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

Review 10.  Adenosine-to-inosine RNA editing in neurological development and disease.

Authors:  Yuxi Yang; Shunpei Okada; Masayuki Sakurai
Journal:  RNA Biol       Date:  2021-01-06       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.